Swiss National Bank reduced its position in shares of Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) by 10.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 24,600 shares of the company’s stock after selling 2,800 shares during the period. Swiss National Bank’s holdings in Deciphera Pharmaceuticals were worth $555,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA grew its holdings in Deciphera Pharmaceuticals by 61,033.3% during the first quarter. BNP Paribas Arbitrage SA now owns 1,834 shares of the company’s stock worth $43,000 after acquiring an additional 1,831 shares during the period. Janus Henderson Group PLC grew its holdings in Deciphera Pharmaceuticals by 2.1% during the second quarter. Janus Henderson Group PLC now owns 675,707 shares of the company’s stock worth $15,237,000 after acquiring an additional 14,028 shares during the period. Bank of America Corp DE grew its holdings in Deciphera Pharmaceuticals by 1,506.1% during the fourth quarter. Bank of America Corp DE now owns 23,561 shares of the company’s stock worth $494,000 after acquiring an additional 22,094 shares during the period. CIBC Asset Management Inc acquired a new position in Deciphera Pharmaceuticals during the first quarter worth about $958,000. Finally, Marshall Wace North America L.P. grew its holdings in Deciphera Pharmaceuticals by 4,025.4% during the first quarter. Marshall Wace North America L.P. now owns 57,714 shares of the company’s stock worth $1,340,000 after acquiring an additional 56,315 shares during the period. 45.68% of the stock is currently owned by hedge funds and other institutional investors.
A number of research analysts recently issued reports on the company. Leerink Swann reaffirmed a “positive” rating and set a $29.00 target price (up from $20.00) on shares of Deciphera Pharmaceuticals in a report on Wednesday, August 14th. Deutsche Bank initiated coverage on Deciphera Pharmaceuticals in a research report on Thursday, July 18th. They issued a “buy” rating and a $42.00 price target for the company. Guggenheim increased their price target on Deciphera Pharmaceuticals from $44.00 to $66.00 and gave the company a “buy” rating in a research report on Tuesday, August 13th. Piper Jaffray Companies increased their price target on Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Monday, June 3rd. They noted that the move was a valuation call. Finally, ValuEngine lowered Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 13th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $48.00.
Shares of NASDAQ:DCPH traded up $0.37 during midday trading on Friday, reaching $36.85. The company had a trading volume of 398,350 shares, compared to its average volume of 968,749. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.26 and a current ratio of 7.26. Deciphera Pharmaceuticals Inc has a 1-year low of $18.55 and a 1-year high of $42.99. The firm has a market cap of $1.80 billion, a price-to-earnings ratio of -13.07 and a beta of 1.92. The company has a fifty day simple moving average of $31.28 and a two-hundred day simple moving average of $25.65.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its quarterly earnings results on Friday, August 2nd. The company reported ($0.56) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.12) by $0.56. The company had revenue of $25.00 million during the quarter, compared to analyst estimates of $20.00 million. Analysts expect that Deciphera Pharmaceuticals Inc will post -4.21 EPS for the current year.
In other news, major shareholder New Leaf Venture Management Ii sold 350,000 shares of Deciphera Pharmaceuticals stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $36.42, for a total transaction of $12,747,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Michael Douglas Taylor sold 7,500 shares of Deciphera Pharmaceuticals stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $36.26, for a total value of $271,950.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at $271,950. The disclosure for this sale can be found here. Insiders sold a total of 539,534 shares of company stock valued at $20,465,526 in the last quarter. 7.02% of the stock is currently owned by corporate insiders.
Deciphera Pharmaceuticals Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
Further Reading: What is an inverted yield curve?
Want to see what other hedge funds are holding DCPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Deciphera Pharmaceuticals Inc (NASDAQ:DCPH).
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.